The financials
Amneal Pharmaceuticals, Inc. by the numbers
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $723M in Q1 2026 (quarter ended Mar 31, 2026), up 3.9% from the same quarter a year earlier. That came with a gross margin of 44% and net income of $62M (8.6% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in Jun 2026 was Subtotal Therapeutic Classes at $149M, 19% of the disclosed total, ahead of Central Nervous System at 12%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $723M | $695M | +3.9% |
| Gross profit | $320M | $256M | +25% |
| Operating income | $142M | $100M | +41% |
| Net income | $62M | $12M | +411% |
| Diluted EPS | $0.19 | $0.04 | +375% |
| Product | Revenue | Share |
|---|---|---|
| Subtotal Therapeutic Classes | $149M | 19% |
| Central Nervous System | $95M | 12% |
| Distribution Service | $87M | 11% |
| Other Dosage Forms | $82M | 11% |
| Transdermal | $67M | 8.7% |
| Ephinephrine Auto Injector | $62M | 8.1% |
| Injectable | $57M | 7.4% |
| Government Label | $50M | 6.5% |
| Hormonal Allergy | $42M | 5.5% |
| Biosimilar | $29M | 3.8% |
| Institutional | $12M | 1.6% |
| Other Therapeutic Classes | $12M | 1.5% |
| Oral Liquid | $10M | 1.3% |
| Product And Service Other | $7.7M | 1.0% |
| International | $7.6M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $770.3M (+13%)
International grew +300% year on yearLicense Agreement -100% year on year
Segment Latestquarter on quarteryear on year
- Subtotal Therapeutic Classes$149.3M$149.3MQoQ +12%year on year +17%+12%+17%
- Central Nervous System$95.3M$95.3MQoQ +14%year on year +14%+14%+14%
- Distribution Service$86.9M$86.9MQoQ -2.5%year on year -13%-2.5%-13%
- Other Dosage Forms$81.6M$81.6MQoQ +75%year on year +20%+75%+20%
- Transdermal$67.0M$67.0MQoQ -9.4%year on year +65%-9.4%+65%
- Ephinephrine Auto Injector$62.2M$62.2MQoQ +48%year on year -6.6%+48%-6.6%
- Injectable$56.8M$56.8MQoQ +14%year on year +64%+14%+64%
- Government Label$50.2M$50.2MQoQ -16%year on year +11%-16%+11%
- Hormonal Allergy$42.1M$42.1MQoQ +17%year on year +19%+17%+19%
- Biosimilar$29.1M$29.1MQoQ +31%year on year +15%+31%+15%
- Institutional$12.1M$12.1MQoQ +23%year on year +20%+23%+20%
- Other Therapeutic Classes$11.9M$11.9MQoQ -15%year on year +36%-15%+36%
- Oral Liquid$10.4M$10.4MQoQ -14%year on year -42%-14%-42%
- Product And Service Other$7.7M$7.7MQoQ +9.0%year on year -1.1%+9.0%-1.1%
- International$7.6M$7.6MQoQ +43%year on year +300%+43%+300%
- License Agreement$0.00$0.00QoQ -year on year -100%--100%
Drug Manufacturers - Specialty & Generic
Ranks #22 of 29 by Smart Score